Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop?

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)
Part of the following topical collections:
  1. Topical Collection on Antiphospholipid Syndrome

Abstract

Antiphospholipid syndrome (APS) is an auto-immune thrombophilia for which anti-thrombotic medication is necessary for long-term management to reduce thrombotic risk or pregnancy morbidity. Choosing the type of pharmacological treatment, i.e. the intensity and duration of anticoagulation, depends on the severity of an individual’s APS and the risk of bleeding. This article reviews the current literature on anticoagulation therapy, provides recommendations on when to initiate therapy, and suggests possible alternatives for optimisation of management.

Keywords

Antiphospholipid syndrome (APS) Antiphospholipid (aPL) Systemic lupus erythematosus (SLE) Anticoagulation therapy Intensity Duration Thromboprophylaxis Refractory APS Thrombosis 

Notes

Conflict of Interest

Sinthiya Punnialingam declares that she has no conflict of interest.

Munther A. Khamashta declares that he has no conflict of interest.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295–306.PubMedCrossRefGoogle Scholar
  2. 2.
    Kearon C, Gent M, Hirsh J, et al. A comparison of three month anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Eng J Med. 1999;340:901–7.CrossRefGoogle Scholar
  3. 3.
    Rosove MH, Brewer PM. Anti-phospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Int Med. 1992;117:303–8.PubMedGoogle Scholar
  4. 4.
    Cervera R, Piette JC, Font J, et al. Antiphospholipid Syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.PubMedCrossRefGoogle Scholar
  5. 5.
    • Aguilar-Valenzuela R, Martínez-Martínez LA, Pierangeli SS. A Comprehensive Review of Thrombogenic Mechanisms in APS. Open Autoimmun J. 2012;2:58–66. This review evaluates the current literature on in-vivo and in-vitro studies of the different intracellular events induced by aPL Abs and its thrombogenic effects.CrossRefGoogle Scholar
  6. 6.
    Sciascia S, Lopez-Pedrera C, De Roccatello. Catastrophic antiphospholipid syndrome (CAPS). Best Pract Res Clin Rheumatol. 2012;26:535–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Esmon NL, Safa O, Smirnov M, et al. Antiphospholipid antibodies and the protein C pathway. J Autoimmun. 2000;15:221–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002;61:46–50.Google Scholar
  9. 9.
    Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphophospholipid syndrome. J Clin Invest. 2003;112:1644–50.PubMedGoogle Scholar
  10. 10.
    Giron-Gonzalez JA, del Río EG, Rodríguez C, et al. Anti-phospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560–7.PubMedGoogle Scholar
  11. 11.
    Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Current Medical Research and Opinion. 2007;23:163–17.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206–18. This important report provides a set of recommendations based on systematic reviews and meta-analysis of all studies concerning management of thrombosis in APS with expert opinions from physicians from different specialities involved in APS.PubMedCrossRefGoogle Scholar
  15. 15.
    Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487–95.PubMedCrossRefGoogle Scholar
  16. 16.
    Wallace DJ. Antimalarials agents and lupus. Rheum Dis Clin North Am. 1994;20:243–63.PubMedGoogle Scholar
  17. 17.
    Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice. Circulation. 1997;96:4380–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30:1435–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Wallace DJ, Kinker-Isreli M, Metzger AL, et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus. 1993;2:S13–5.PubMedCrossRefGoogle Scholar
  20. 20.
    McCarty GA. Hydroxychloroquine (HCQ) treatment in antiphospholipid antibody syndrome (APS): time course of clinical improvement and antiphospholipid antibody (aPL) titer changes over 4 years [abstract]. Arthritis Rheum. 2000;43 Suppl 9:S1061.Google Scholar
  21. 21.
    Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with anti-phospholipid syndrome. N Eng J Med. 2003;349:1133–8.CrossRefGoogle Scholar
  22. 22.
    Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol. 2011;154:1365–2141.CrossRefGoogle Scholar
  24. 24.
    Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med. 1995;332:993–7.PubMedCrossRefGoogle Scholar
  25. 25.
    • Cervera R, Khamashta MA, Shoenfeld Y, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Tan BE, Thong BY, Shivananda S, et al. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus. 2009;18:752–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Okuma H, Kitagawa Y, Yasuda T, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci. 2009;7:15–8.PubMedGoogle Scholar
  29. 29.
    Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.PubMedCrossRefGoogle Scholar
  30. 30.
    Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.PubMedCrossRefGoogle Scholar
  31. 31.
    • Pengo V, Ruiz-Irastorza G, Denas G, et al. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev. 2012;11:577–80. This review evaluates the importance of designing better prospective studies with regard to APS patients and to standardise criteria for APS patients in studies to avoid future conflicting results.PubMedCrossRefGoogle Scholar
  32. 32.
    Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Pattison NS, Chamley LW, McKay EJ, et al. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol. 1993;100:909–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Lockwood CJ, Romero R, Feinberg RF, et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;161:369–73.PubMedGoogle Scholar
  35. 35.
    Yasuda M, Takakuwa K, Tokunaga A, et al. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555–9.PubMedGoogle Scholar
  36. 36.
    Derksen RHWM, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum. 2004;50:1028–39.PubMedCrossRefGoogle Scholar
  37. 37.
    Danza A, Ruiz-Irastorza G, Khamashta M. Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2012;26:65–76.PubMedCrossRefGoogle Scholar
  38. 38.
    Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166:1318–23.PubMedGoogle Scholar
  39. 39.
    Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol. 1993;169:1411–7.PubMedGoogle Scholar
  40. 40.
    Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 1996;35:402–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Rai R, Regan L. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment [letter]. Obstet Gynecol. 2002;100:1354.PubMedCrossRefGoogle Scholar
  42. 42.
    Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines. Regional anesthesia and pain medicine. 2010;35:64–101.PubMedCrossRefGoogle Scholar
  43. 43.
    Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. Semin Thromb Hemost. 2012;38:339–47.PubMedCrossRefGoogle Scholar
  44. 44.
    Pengo V, Denas G, Banzato A, et al. Secondary prevention in thrombotic antiphospholipid syndrome. Lupus. 2012;21:734–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, et al. Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70:1652–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Jajoria P, Murthy V, Papalardo E, Romay-Penabad Z, Gleason C, Pierangeli SS. Statins for the Treatment of Antiphospholipid Syndrome? Ann NY Acad Sci. 2009;1173:736–45.PubMedCrossRefGoogle Scholar
  47. 47.
    Kumar D, Roubey RA. Use of rituximab in the antiphospholipidsyndrome. Curr Rheumatol Rep. 2010, 12:40–44Google Scholar
  48. 48.
    Adamson R, Sangle S, Kaul A, et al. Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol. 2008;14:359–60.PubMedCrossRefGoogle Scholar
  49. 49.
    Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.PubMedCrossRefGoogle Scholar
  50. 50.
    Linkins LA, Weitz JI. New anticoagulants. Semin Thromb Hemost. 2003;29:619–31.PubMedCrossRefGoogle Scholar
  51. 51.
    Schulman S, Svenungsson E, Granqvist S. Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Kearon C, Kahn SR, Agnelli G, et al. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454S–545S.PubMedCrossRefGoogle Scholar
  53. 53.
    •• Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis rheum. 2012;64:504–12. This article investigates the use of a score which all physicians can easily use in common clinical practice to improve the efficiency of identifying severe APS patients to provide the best possible management.PubMedCrossRefGoogle Scholar
  54. 54.
    Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Antiphospholipid Syndrome Score. Rheumatology. Rheumatology (Oxford). 2013. doi: 10.1093/rheumatology/kes388.

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of General MedicineGuy’s and St Thomas’ HospitalLondonUK
  2. 2.Graham Hughes Lupus Research Laboratory, Rayne InstituteSt Thomas’ HospitalLondonUK

Personalised recommendations